Targeted drug therapies have greatly improved outcomes for patients with relapsed or
refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. However,
single drug therapies have limitations, therefore, the current study is evaluating a novel
oral combination of targeted drugs as a way of overcoming these limitations. This study will
determine the efficacy of the triple combination therapy, DTRM-555, in patients with R/R CLL
or R/R non-Hodgkin's lymphoma.
This study is being conducted in three parts: Phase Ia, Phase Ib and Phase II,
disease-specific expansion cohorts. Phase Ia explored escalating doses of a monotherapy of a
novel Bruton's Tyrosine Kinase (BTK) inhibitor, DTRMWXHS-12. Phase Ib explored two
combination therapies, DTRM-505 (DTRMWXHS-12 and everolimus) and DTRM-555 (DTRMWXHS-12,
everolimus and pomalidomide).
The current Phase II study will further examine the investigational triple combination
treatment, DTRM-555 for efficacy and safety. The study is being conducted in five
disease-specific cohorts: Activated B-Cell (ABC) Diffuse Large B-Cell Lymphoma, Germinal
Center B-Cell (GCB) Diffuse Large B-Cell Lymphoma, Richter's Transformation, transformed
Follicular Lymphoma, and relapsed or refractory Chronic Lymphocytic Leukemia.
The Primary Objective of the Phase II study is to determine the efficacy of the triple
combination therapy, DTRM-555, in the five disease-specific cohorts. The Secondary Objectives
are (1) to determine the safety of DTRM-555 in the cohorts and (2) to obtain the
pharmacokinetics of DTRM-555 (i.e., DTRMWXHS-12, everolimus and pomalidomide).
- Patients must provide written informed consent.
- Patients with a diagnosis of R/R CLL or other B-cell neoplasms (i.e., ABC DLBCL, GCB
DLBCL, Richter's transformation and tFL) who have no available approved therapies, or
patients with a diagnosis of non-Hodgkin's lymphoma, which has relapsed and/or is
refractory to standard therapy.
a. Patients with R/R CLL must have been exposed to Bruton's tyrosine kinase (BTK) or
B-Cell CLL/Lymphoma 2 (BCL2) inhibitor-based therapy in prior lines of therapy but
must not have known Cys481 resistance mutation prior to study enrollment.
- Age ≥ 18 years.
- Life expectancy greater than 12 weeks.
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of
0 or 1.
- Ability to swallow and retain capsules and/or tablets.
- Absence of uncontrolled intercurrent illnesses, including uncontrolled infections,
cardiac conditions, or other organ dysfunctions.
- If the patient consents to an optional tumor biopsy, he/she must have a tumor that can
be safely biopsied and undergo a baseline tumor biopsy procedure, or be willing to
provide available archival tissue collected within 6 months of signing the Informed
Consent Form (ICF), and one post-Cycle 1 treatment biopsy.
- Patients must have at least one target lesion according to Lugano Classification.
Patients with R/R CLL are exempt from this requirement.
- Women of child-bearing potential must have a negative serum or urine pregnancy test.
- Women of child-bearing potential must agree to use 2 reliable methods of contraception
beginning 4 weeks prior to the initiation of treatment, during therapy, and for at
least 4 weeks after the last drug administration.
- Men must agree to use a latex or synthetic condom during sexual contact with a
pregnant female or a female of child-bearing potential, for the duration of the study
and for at least 4 weeks after the last drug administration, even if they have
undergone a successful vasectomy.
- Received prior systemic anticancer treatment within the following time frames:
1. Chemotherapy, immunotherapy, radiotherapy or any other investigational therapy
within 21 days prior to starting study treatment.
2. Targeted therapies within 5 biological half-lives prior to starting study
- Patients with active infections requiring therapy are not eligible for entry into the
study until resolution of the infection; however, patients on prophylactic
antibiotics, antifungals or antivirals are eligible for entry into the study.
- Pregnant or lactating individuals.
- Impaired hepatic or renal function as demonstrated by any of the following laboratory
1. Aspartate transaminase (AST) or alanine transaminase (ALT) > 2.5 x upper limit of
normal (ULN); for patients with liver involvement, > 5 x ULN
2. Total bilirubin > 1.5 x ULN (Patients with a history of Gilbert's syndrome may
participate if total bilirubin is less than or equal to 3 x ULN and the AST/ALT
and alkaline phosphatase meet the protocol-specified levels for eligibility)
3. Alkaline phosphatase > 2.5 x ULN
4. Glomerular filtration rate < 50 mL/min, as assessed using the standard
methodology at the investigating center (i.e., Cockcroft-Gault), or serum
creatinine > 1.5 x ULN
- International normalized ratio (INR) > 1.5 or other evidence of impaired hepatic
- Absolute neutrophil count < 1.0 x 109/L or platelets < 100 x 109/L, unless due to
disease-related bone marrow impairment as confirmed by bone marrow biopsy during
screening or due to standard of care treatment within 2 months prior to signing of
informed consent. Patients with bone marrow impairment will be excluded if their
absolute neutrophil count (ANC) is < 0.5 x 109/L and platelets < 50 x 109/L.
- Previous allogeneic bone marrow transplant is restricted, unless transplant was
greater than 3 months prior and there is no evidence of acute or chronic graft versus
- Central nervous system involvement with malignancy.
- Patients who have poorly controlled diabetes mellitus or whose glucose values cannot
be controlled with medical treatment.
- Current malignancies of another type, with the exception of adequately treated in situ
cervical cancer and basal cell skin cancer, squamous cell carcinoma of the skin or
other malignancies with no evidence of disease for 2 years or more.
- Known history of human immunodeficiency virus (HIV), hepatitis B virus (HBV), or
hepatitis C virus (HCV) infection.
- Documented or known bleeding disorder.
- Requirement for anticoagulation treatment that increases INR or activated partial
thromboplastin time above the normal range (low molecular weight heparin and heparin
line flush allowed).
- Patients requiring the use of strong CYP3A4, CYP1A2, or P-gp inhibitors.
- Patients with a significant cardiovascular disease or condition, including:
1. myocardial infarction within 6 months of study entry,
2. New York Heart Association Class III or IV heart failure,
3. uncontrolled dysrhythmias or poorly controlled angina,
4. history of serious ventricular arrhythmia (ventricular fibrillation or
ventricular tachycardia, ≥ 3 beats in a row) and/or risk factors (e.g., heart
failure, hypokalemia, or family history of Long QT Syndrome),
5. baseline prolongation of QT/QTc interval (repeated demonstration of corrected QT
interval (QTc) ≥ 450 msec for men and 470 msec for women), and
6. left ventricular ejection fraction (LVEF) < 45% by multiple gated acquisition
(MUGA) and /or echocardiogram (ECHO)